Document Detail


Ovarian cancer as a genetic disease.
MedLine Citation:
PMID:  23276941     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ovarian cancer is characterized by the highest mortality rate among gynecologic malignancies. Therefore, there is a growing need for innovative therapies and techniques for monitoring and prevention of this disease. The exact cause of most ovarian tumors usually remains unknown. Ovarian cancer is believed to be caused by a range of different variables. This review is an attempt to summarize some genetic factors involved in the disruption of certain signaling pathways responsible for ovarian tumor transformation and development. Those factors considerably contribute to accurate diagnostics, treatment and prognosis in ovarian cancer.
Authors:
Agnieszka Lech; Teodora Daneva; Shina Pashova; Hristo Gagov; Robert Crayton; Wojciech Kukwa; Anna M Czarnecka; Cezary Szczylik
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  543-63     Citation Subset:  IM    
Affiliation:
Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Transformation, Neoplastic / genetics*
Female
Genes, BRCA1 / physiology
Genes, BRCA2 / physiology
Genes, p53 / physiology
Humans
Ovarian Neoplasms / genetics*
Precancerous Conditions / genetics*
Prognosis
Signal Transduction / genetics

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.
Next Document:  Biomarker discovery by plasma proteomics in familial Brugada Syndrome.